Raymond James & Associates Reata Pharmaceuticals Inc Transaction History

Raymond James & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 28, 2020	SELL	$126.3 - $176.56 $651,202 - $910,343	-5,156 Closed	0 $0
Q1 2020 Apr 21, 2020	BUY	$124.16 - $247.74 $385,640 - $769,480	3,106 Added 151.51%	5,156 $744,000
Q4 2019 Feb 12, 2020	SELL	$74.57 - $217.92 $167,036 - $488,140	-2,240 Reduced 52.21%	2,050 $419,000
Q3 2019 Nov 07, 2019	BUY	$71.26 - $95.75 $10,689 - $14,362	150 Added 3.62%	4,290 $344,000
Q2 2019 Aug 06, 2019	BUY	$77.72 - $94.35 $321,760 - $390,609	4,140 New	4,140 $391,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.